Clinical trials across several therapy areas have been severely affected by the ongoing Covid-19 pandemic.
GlobalData conducted a survey to identify primary business concerns related to the coronavirus outbreak by company role.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Primary Clinical Trial Concerns Related to the Covid-19 Outbreak by Company Role
An assessment of the survey reveals that the concerns regarding inability or delays in initiating clinical trials mostly dominate across all respondent groups.
Around 34% of the contract research organisations (CROs) identified such delays as their primary concern, while 30% of other contract service providers felt the same.
Approximately 29% of government/academic institutes, 27% of clinical/ investigator sites and 27% of Pharma/ Biotech also highlighted the inability or delay to initiate clinical trials as the primary concern.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataImpact on clinical trial participants was the highest concern among other contract service providers (29%), followed by Pharma/ Biotech (28%), CROs (24%), government/academic institutes (21%) and clinical/ investigator sites (18%).
Clinical/Investigator sites (32%) were most worried about the safety of the patients recruited in trials. Around 29% of government/academic institutes, 26% of CROs, 24% of Pharma/ Biotech organisations and 19% of other contract service providers shared similar views.
The survey also found that the government/academic institutes (21%) were the most concerned respondent group about the negative impact on planned goals submitted to regulatory agencies compared with others. The figure stood at 13% for Pharma/ Biotech, 13% for other contract service providers, 9% for clinical/investigator sites and 6% for CROs.
Around 9% of clinical/investigator sites were most concerned about loss of investment. The percentage stood at 8%, 8% and 6% for Pharma/ Biotech, CROs and other contract service providers, respectively.
Around 5% of clinical/investigator sites, 4% of other contract service providers, 2% of CROs and 1% of Pharma/ Biotech cited other concerns.
The analysis is based on responses received for the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.
